EKF Diagnostics Holdings PLC

Chart & Performance

D1W1MN

P/E

5,218.29

P/S

233.29

EPS

0.01

Div Yield, %

0.04%

Shrs. gr., 5y

-0.32%

Rev. gr., 5y

4.34%

Revenues

53m

-21.05%

Net income

CFO

-34.86%

Dividend

Nov 02, 20231.2 GBP/sh

Earnings

Mar 18, 2025

Profile

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

URL

https://www.ekfdiagnostics.com/

IPO date

Jun 05, 2002

Employees

356

Domiciled in

Incorporated in

Valuation

Order:

Title GBP in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title GBP in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	52,611 -21.05%	66,635 -18.57%
Cost of revenue	48,455	67,292
Unusual Expense (Income)
NOPBT	4,156	(657)
NOPBT Margin	7.90%
Operating Taxes	(600)	634
Tax Rate
NOPAT	4,756	(1,291)
Net income	2,352 -124.56%	(9,576) -160.41%
Dividends	(5,445)	(5,459)
Dividend yield	3.79%	2.39%
Proceeds from repurchase of equity		(3,896)
BB yield		1.70%
Debt
Debt current	3,481	1,010
Long-term debt	1,731	1,947
Deferred revenue
Other long-term liabilities
Net debt	(1,084)	(9,740)
Cash flow
Cash from operating activities	6,311	9,688
CAPEX	(6,598)	(5,828)
Cash from investing activities	(5,642)	(8,932)
Cash from financing activities	(3,646)	(11,039)
FCF	(2,874)	73
Balance
Cash	6,020	11,578
Long term investments	276	1,119
Excess cash	3,665	9,365
Stockholders' equity	60,830	67,148
Invested Capital	68,651	64,265
ROIC	7.16%
ROCE	5.55%
EV
Common stock shares outstanding	454,105	457,180
Price	0.32 -36.70%	0.50 -33.33%
Market cap	143,724 -37.13%	228,590 -33.88%
EV	143,740	220,027
EBITDA	9,628	6,001
EV/EBITDA	14.93	36.67
Interest	75	102
Interest/NOPBT	1.80%